Exonhit Enters Into Research Agreement with Pfizer

As part of the agreement, the two companies will jointly conduct a pilot study using Exonhit’s GWSA platform to gain insight on Alzheimer’s disease (AD) molecular markers associated with clinical parameters. More specifically, the purpose of the research work is to seek to identify progression and other biomarkers that could segregate healthy elderly controls, patients with mild cognitive impairment (MCI) and patients with AD. Test samples for the study will be provided by Pfizer from a number of subjects in each of these three groups over a period of time.

“Today’s announcement further demonstrates the interest in the potential of our GWSA discovery platform,” said Loïc Maurel M.D., President of Exonhit’s Management Board. “We are excited to collaborate with Pfizer and we hope that this study will identify new Alzheimer’s biomarkers and hence lead to the potential development of prognostic tests for patients”.

Dr. Aidan Power, Vice President and Head of Pharma Therapeutics Precision Medicine at Pfizer, added: “Pfizer is committed to making a number of investments to evaluate technology platforms with the potential to identify new biomarkers of Alzheimer’s disease. Our collaboration with ExonHit is one such example of this commitment. The discovery and validation of new AD biomarkers is important for Pfizer’s effort to bring forward new treatment options for Alzheimer’s patients as well as for the development of improved diagnostics.”

Financial details were not disclosed.